Role of insulin-like growth factor monitoring in optimizing growth hormone therapy

Journal of Pediatric Endocrinology and Metabolism

Volumn 13, Issue SUPPL. 6, 2000, Pages 1371-1376

  Wetterau, L ^a   Cohen, P ^a  

^a MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

Growth hormone deficiency; Growth hormone therapy; Insulin like growth factor binding protein 3; Insulin like growth factor I; Pediatric growth hormone deficiency

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

BLOOD LEVEL; BODY HEIGHT; CONFERENCE PAPER; DRUG SAFETY; GROWTH HORMONE DEFICIENCY; GROWTH RATE; HORMONE SUBSTITUTION; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 0034519869     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/jpem-2000-s610     Document Type: Conference Paper

References (29)

1. The growth hormone cascade: Progress and long-term results of growth hormone treatment in growth hormone deficiency
2. Outcome of a four-year randomized study of daily versus three times weekly somatotropin treatment in prepubertal naïve growth hormone deficient children
3. Long-term follow-up of hypopituitary patients treated with human growth hormone
4. Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH
5. Final height of growth hormone-treated patients with growth hormone deficiency: The North American experience
6. Final height in idiopathic growth hormone deficiency: The KIGS experience
7. Optimizing growth hormone therapy in children
8. Daily subcutaneous administration of human growth hormone in growth hormone deficient children
9. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: Effects on 24-hour patterns of circulating hormones and metabolites
10. Diagnosis and treatment of growth hormone deficiency in children and adolescents: Towards a consensus
11. A dose-response curve for human growth hormone
12. Dose response effects of growth hormone on auxological and biochemical parameters in GH deficient children
13. Dosing of growth hormone in growth hormone deficiency
14. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency
15. Prediction of growth response in prepubertal children treated with growth hormone for idiopathic growth hormone deficiency
16. Determination of IGF-I in the monitoring of growth hormone treatment with respect to efficacy of treatment and side effects: Should potential risks of cardiovascular disease and cancer be considered?
17. Invited Report of a Workshop: Consensus Guidelines for the Diagnosis and Treatment of Growth Hormone Defieciency in Childhood and Adolescence: Summary Statement of the Growth Hormone Research Society on Child and Adolescent Growth Hormone Deficiency
18. The response of the insulin-like growth factor binding protein 3 complex to growth hormone
19. Insulin-like growth factors and IGF-binding proteins: Their use for diagnosis of growth hormone deficiency
20. IGFs and human cancer: Implications regarding the risk of growth hormone therapy
21. Serum insulin-like growth factor-I levels and prostate cancer risk - Interpreting the evidence
22. Insulin-like growth factor-I and prostate cancer risk: A population-based, case-control study
23. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
24. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
25. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis
26. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3
27. Guidelines for the use of growth hormone in children with short stature: A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society
28. Factors determining pubertal growth and final height in growth hormone deficiency. Analysis of 195 patients of the Kabi International Growth Study
29. The effects of growth hormone therapy on spontaneous sexual development